$NVZMY

Novonesis reports 7% Q1 organic growth and 37.8% EBITDA margin, confirms full-year guidance, and secures EUR 1.7B in bond financing plus Thailand facility acquisition.

Novonesis reported 7% Q1 organic sales growth, 37.8% EBITDA margins, and secured €1.7B funding while acquiring a Thai production facility for expansion.

Arla Foods Ingredients launches specialized high-protein nutrition products for GLP-1 medication users, debuting at Vitafoods Europe 2026.

Novonesis acquires Thai HMO production facility for $50 million, targeting 2027 commercial operation to expand Southeast Asia presence and support GROW 2030 strategy.

Novonesis raises €1.7B in senior unsecured notes with 3.25%-4.00% coupons under new €4B EMTN programme, with proceeds for debt refinancing and corporate purposes.

Novo Holdings achieved 9.2% portfolio return in 2025 but total AUM fell 35% to DKK 694B, primarily due to Novo Nordisk valuation decline.